News

FDA Grants Approval to Blinatumomab Consolidation Therapy for CD19-Positive Philadelphia Chromosome-Negative B-cell Precursor ALL

06/21/2024

The FDA granted approval to blinatumomab for adult and pediatric patients with CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia (ALL) in the consolidation phase of multi-phase chemotherapy.

The FDA granted approval to...

06/21/2024

Oncology

News

Mini-Hyper-CVD Plus Venetoclax Yields Safety and Activity Among Patients With Heavily Pretreated R/R ALL

04/09/2024

Jordan Kadish

According to a phase 1/2 trial, combining mini-hyper-CVD low-intensity chemotherapy with venetoclax yielded safety and activity among patients with heavily pretreated R/R acute lymphoblastic leukemia.

According to a phase 1/2 trial,...

04/09/2024

Oncology

News

Allogeneic Stem Cell Transplantation in First Complete Remission for Patients With Philadelphia Chromosome-Positive ALL

04/01/2024

Jordan Kadish

Patients with Philadelphia chromosome-positive acute lymphoblastic leukemia who received allogeneic stem cell transplantation in the first complete remission demonstrated superior survival outcomes compared with patients who did not undergo...

Patients with Philadelphia...

04/01/2024

Oncology

FDA Approval

FDA Approves Ponatinib With Chemotherapy for Patients With Newly-Diagnosed Ph-Positive Acute Lymphoblastic Leukemia

03/21/2024

Jordan Kadish

On March 19, 2024, the US FDA granted accelerated approval to ponatinib with chemotherapy for patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia.

On March 19, 2024, the US FDA...

03/21/2024

Oncology

News

Imatinib vs Dasatinib Prophylaxis Among Patients With Philadelphia-Positive ALL Post-Transplantation

03/15/2024

Jordan Kadish

Imatinib prophylaxis demonstrated outcomes comparable to dasatinib among patients with Philadelphia-positive acute lymphoblastic leukemia after allogeneic stem cell transplantation at first complete remission, according to a retrospective...

Imatinib prophylaxis...

03/15/2024

Oncology

News

FDA Grants Approval to Inotuzumab Ozogamicin for Pediatric Patients With R/R CD22-Positive B-Cell Precursor ALL

03/07/2024

Jordan Kadish

On March 6, 2024, the FDA approved inotuzumab ozogamicin for pediatric patients with relapsed/refractory CD22-positive B-cell precursor acute lymphoblastic leukemia.

On March 6, 2024, the FDA...

03/07/2024

Oncology

News

Chemo-Free Induction/Consolidation With Dasatinib and Blinatumomab Shows Long-Term Responses for Adult Patients With Philadelphia-Positive ALL

02/21/2024

Jordan Kadish

Chemotherapy-free induction/consolidation with dasatinib and blinatumomab prompted durable long-term responses among adult patients with Philadelphia-positive acute lymphoblastic leukemia, according to the final analysis of the D-ALBA trial.

Chemotherapy-free...

02/21/2024

Oncology

News

Dose-Dense Mini-Hyper-CVD, Inotuzumab Ozogamicin, and Blinatumomab Shows Safety, Efficacy Among Patients With Philadelphia Chromosome-Negative B-Cell ALL

02/13/2024

Jordan Kadish

Dose-dense mini-hyper-CVD, inotuzumab ozogamicin, and blinatumomab yields rapid and deep MRD-negativity and safety among patients with Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia, according to a retrospective...

Dose-dense mini-hyper-CVD,...

02/13/2024

Oncology

News

Pegaspargase-Modified Risk-Oriented Regimen for Patients With Philadelphia Chromosome–Negative ALL

10/24/2023

Amber Denham

The addition of a pegaspargase-modified risk-oriented program to treatment regimens improved outcomes for patients with Philadelphia chromosome–negative acute lymphoblastic leukemia/lymphoma, according to the GIMEMA LAL1913 trial.

The addition of a...

10/24/2023

Oncology

News

Third-Generation CD19-Directed CAR-T Cell Treatment Shows Promising Efficacy for Patients With R/R ALL

09/25/2023

Amber Denham

Third-generation CAR-T cells for the treatment of patients with relapsed/refractory ALL were associated with promising clinical efficacy and low procedure-specific toxicity, according to the first report of a phase 1/2 trial.

Third-generation CAR-T cells for...

09/25/2023

Oncology

Recent News

News

Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation

08/08/2024

Stephanie Holland ;

Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.

Results from a phase 2 study...

08/08/2024

Oncology

FDA Approval

FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma

08/08/2024

Amber Denham ;

The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.

The US Food and Drug...

08/08/2024

Oncology

News

Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer

08/07/2024

Stephanie Holland ;

According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.

According to results from the...

08/07/2024

Oncology

News

Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL

08/07/2024

Amber Denham ;

A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.

A recent study demonstrated that...

08/07/2024

Oncology

News

Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer

08/07/2024

Stephanie Holland ;

Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.

Results from a phase 2 study...

08/07/2024

Oncology

FDA Approval

FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma

08/06/2024

Stephanie Holland ;

Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.

Based on results from the INDIGO...

08/06/2024

Oncology

FDA Approval

FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma

08/02/2024

Allison Casey ;

On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...

On August 2, 2024, the US Food...

08/02/2024

Oncology

FDA Approval

FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer

08/01/2024

Allison Casey ;

The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.

The FDA approved dostarlimab...

08/01/2024

Oncology

News

Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML

08/01/2024

Amber Denham ;

The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.

The first-line combination of...

08/01/2024

Oncology

News

Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

08/01/2024

Allison Casey ;

In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...

In the phase 1 trial, the...

08/01/2024

Oncology